Abstract
The ability of clinicians to wage an effective war against many bacterial infections is increasingly being hampered by skyrocketing rates of antibiotic resistance. Indeed, antibiotic resistance is a significant problem for treatment of diseases caused by virtually all known infectious bacteria. The gastric pathogen Helicobacter pylori is no exception to this rule. With more than 50% of the worlds population infected, H. pylori exacts a tremendous medical burden and represents an interesting paradigm for cancer development; it is the only bacterium that is currently recognized as a carcinogen. It is now firmly established that H. pylori infection is associated with diseases such as gastritis, peptic and duodenal ulceration and two forms of gastric cancer, gastric adenocarcinoma and mucosa-associated lymphoid tissue (MALT) lymphoma. With such a large percentage of the population infected, increasing rates of antibiotic resistance are particularly vexing for a treatment regime that is already fairly complicated; treatment consists of two antibiotics and a proton pump inhibitor. To date, resistance has been found to all primary and secondary lines of antibiotic treatment as well as to drugs used for rescue therapy.
Keywords: Molecular Mechanisms, Antibiotic Resistance, Helicobacter pylori, bacterial infections, gastric pathogen, carcinogen, gastric adenocarcinoma, mucosa-associated lymphoid tissue (MALT)
Current Drug Therapy
Title: Whos Winning the War? Molecular Mechanisms of Antibiotic Resistance in Helicobacter pylori
Volume: 3 Issue: 3
Author(s): Kathleen R. Jones, Jeong-Heon Cha and D. Scott Merrell
Affiliation:
Keywords: Molecular Mechanisms, Antibiotic Resistance, Helicobacter pylori, bacterial infections, gastric pathogen, carcinogen, gastric adenocarcinoma, mucosa-associated lymphoid tissue (MALT)
Abstract: The ability of clinicians to wage an effective war against many bacterial infections is increasingly being hampered by skyrocketing rates of antibiotic resistance. Indeed, antibiotic resistance is a significant problem for treatment of diseases caused by virtually all known infectious bacteria. The gastric pathogen Helicobacter pylori is no exception to this rule. With more than 50% of the worlds population infected, H. pylori exacts a tremendous medical burden and represents an interesting paradigm for cancer development; it is the only bacterium that is currently recognized as a carcinogen. It is now firmly established that H. pylori infection is associated with diseases such as gastritis, peptic and duodenal ulceration and two forms of gastric cancer, gastric adenocarcinoma and mucosa-associated lymphoid tissue (MALT) lymphoma. With such a large percentage of the population infected, increasing rates of antibiotic resistance are particularly vexing for a treatment regime that is already fairly complicated; treatment consists of two antibiotics and a proton pump inhibitor. To date, resistance has been found to all primary and secondary lines of antibiotic treatment as well as to drugs used for rescue therapy.
Export Options
About this article
Cite this article as:
Jones R. Kathleen, Cha Jeong-Heon and Merrell Scott D., Whos Winning the War? Molecular Mechanisms of Antibiotic Resistance in Helicobacter pylori, Current Drug Therapy 2008; 3 (3) . https://dx.doi.org/10.2174/157488508785747899
DOI https://dx.doi.org/10.2174/157488508785747899 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nanofillers for Food Packaging: Antimicrobial Potential of Metal-based Nanoparticles
Current Nanotoxicity and Prevention (Discontinued) Antidepressants: Update on Benefits and Risks
Current Psychopharmacology Recent Advances on the Organocatalytic Asymmetric Aza-Henry Reaction
Current Organocatalysis Disorder in Milk Proteins: α-Lactalbumin. Part B. A Multifunctional Whey Protein Acting as an Oligomeric Molten Globular “Oil Container” in the Anti-Tumorigenic Drugs, Liprotides
Current Protein & Peptide Science Exploration of the Hepatoprotective Effect and Mechanism of Swertia mussotii Franch in an Acute Liver Injury Rat Model
Combinatorial Chemistry & High Throughput Screening Antioxidants in Health, Disease and Aging
CNS & Neurological Disorders - Drug Targets The Immunohistochemical Assessment of HPV Related Adenocarcinoma: Pathologic and Clinical Prognostic Significance
Current Pharmaceutical Design Biodegradable Polymer Based Particulate Carrier(s) for the Delivery of Proteins and Peptides
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Relevance of the Neuropeptide Y System in the Biology of Cancer Progression
Current Topics in Medicinal Chemistry The Potential Therapeutic Role of the HMGB1-TLR Pathway in Epilepsy
Current Drug Targets Profiling and Characterization of microRNAs Responding to Sodium Butyrate Treatment in Gastric Cancer Cells
Combinatorial Chemistry & High Throughput Screening Editorial (Thematic Issue : Recent Advances in Cancer Research: Targets and New Ligands)
Current Pharmaceutical Design New Aspects of Regulatory Signaling Pathways and Novel Therapies in Pancreatic Cancer
Current Molecular Medicine Impact of PLK-1 Silencing on Endothelial Cells and Cancer Cells of Diverse Histological Origin
Current Gene Therapy Recent Advances and Strategies in Tumor Vasculature Targeted Nano-Drug Delivery Systems
Current Pharmaceutical Design Cellular Functions of RNA-Binding Motif Protein 3 (RBM3): Clues in Hypothermia, Cancer Biology and Apoptosis
Protein & Peptide Letters Genistein Down-Regulates miR-223 Expression in Pancreatic Cancer Cells
Current Drug Targets Targeting the Nucleotide Metabolism Proteins of the NUDIX Family and SAMHD1 in Cancer
Current Medicinal Chemistry Recombinant Salmonella Vaccination Technology and Its Application to Human Bacterial Pathogens
Current Pharmaceutical Biotechnology Microemulsion and Microemulsion-Based Gels for Topical Antifungal Therapy with Phytochemicals
Current Pharmaceutical Design